Development asset linked to International Peace Maternity in public FDA and regional records.
pharma · Rheumatoid Arthritis · Cholera
International Peace Maternity
International Peace Maternity and Child Health Hospital
International Peace Maternity drug portfolio — 16 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
CN HQ
NMPA registrant Type
Company details
- Status
- Public
- HQ
- CN
- Programs
- 21
- Drugs
- 16
- Patents
- 0
International Peace Maternity pipeline
Portfolio lens on 16 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
International Peace Maternity drug portfolio — 16 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Drug portfolio
-
-
Development asset linked to International Peace Maternity in public FDA and regional records.
-
Development asset linked to International Peace Maternity in public FDA and regional records.
-
cholera vaccine, oral, live
Antiinfectives for systemic use (J07)Antiinfectives for systemic use (J07) compound in International Peace Maternity's portfolio. Mechanism: Biological vaccine - induces immune response.
- Mechanism
- Biological vaccine - induces immune response
-
Development asset linked to International Peace Maternity in public FDA and regional records.
-
US regulatory status: approved. Molecular target: Bacterial 70S ribosome.
- Target
- Bacterial 70S ribosome
- Mechanism
- Bacterial 70S ribosome inhibitor
-
fenfluramine
Nervous system (N03)US regulatory status: approved. Mechanism: Serotonin 2c (5-HT2c) receptor agonist.
- Mechanism
- Serotonin 2c (5-HT2c) receptor agonist
-
US regulatory status: approved. Molecular target: 5-hydroxytryptamine receptor 1D.
- Target
- 5-hydroxytryptamine receptor 1D
- Mechanism
- Serotonin 2c (5-HT2c) receptor agonist
-
US regulatory status: approved. Molecular target: Lanosterol 14-alpha demethylase.
- Target
- Lanosterol 14-alpha demethylase
- Mechanism
- Cytochrome P450 51 inhibitor
-
US regulatory status: approved. Molecular target: Aromatase.
- Target
- Aromatase
- Mechanism
- Cytochrome P450 19A1 inhibitor
-
Various (V04) compound in International Peace Maternity's portfolio.
-
Development asset linked to International Peace Maternity in public FDA and regional records.
-
Development asset linked to International Peace Maternity in public FDA and regional records. Mechanism: Biological vaccine - induces immune response.
- Mechanism
- Biological vaccine - induces immune response
-
Development asset linked to International Peace Maternity in public FDA and regional records. Mechanism: Estrogen receptor alpha modulator.
- Mechanism
- Estrogen receptor alpha modulator
-
Development asset linked to International Peace Maternity in public FDA and regional records.
-
Development asset linked to International Peace Maternity in public FDA and regional records.